Τόμος 2 (1988) – Τεύχος 2 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 2 (1988) – Issue 2 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. PHARMAKON-Press Information Services, Athens, Greece

2. Laboratory of Drug Metabolism, Department of Pharmacology, University of Geneva, Switzerland.

pharmakonpress[at]pharmakonpress[.]gr

2.         Williams, Κ., Lee, E.: Importance of drug enantiomers in clinical pharmacology. Drugs 30: 333 (1985)

3.         Leemann, T.: Lesprincipes actifs et leursst£r6oisom£resou les faux-freres de la pharmacologie. Μέά. et Hyg. 46:1232 (1988)

4.         Balandrin, M.F., Klocke, J.A., Wurtele, E.S., Bolliger, W.H.: Natural plant chemicals: sources of industrial and medicinal materials. Science 228: 1154 (1985)

5.         Drayer, D.E.: Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin. Pharmacol. Ther. 40: 125 (1986)

6.         Ariens, E.J.: Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26: 663 (1984)

7.         Ariens, E.J., Wuis, E.W.: Bias in pharmacokinetics and clinical pharmacology. Clin. Pharmacol. Ther. 42: 361 (1987) ;

8.         Lipinski, Ch.A.: Bioisosterism in drug design. Ann. Rep. Med. Chem. 21: 283 (1986)

9.         Cahn, R.S., Ingold, C.K., Prelog, V.: Specification of molecular chirality. Angewandte Chemie Int. Edn 5: 358 (1966)

10.       Lawrence, S.U.: Gossypol: a potential male contraceptive? Am. Pharm. 21: 57 (1981)

11.       Plessas, C.T., Plessas, S.T., Varonos, D.: Orugs and sperm. Epitheor. Klin. Farmakol. Farmakokin. Int. Ed. 2: 31 (1988)

12.       Ariens, E.J.: Stereospecificity of bioactive agents. In:

Stereoselectivity of Pesticides: Biological and Chemical Problems (E.J. Ariens, J.J.S. van Rensen, W. Welling, eds). Vol. 1, p. 39, Elsevier, Amsterdam, 1988

13.       Testa, B.: Substrate and product stereoselectivity in monooxygenase-mediated drug activation and inactivation. Biochem. Pharmacol. 37: 85 (1988)

14.       Johnston, G.B., Finch, M.B., McNeill, J.A., Shanks, R.G.: A comparison of the cardiovascular effects of (+)-sotalol and (±)-sotalol following intravenous administration in normal volunteers. Br. J. Clin. Pharmacol. 20: 507 (1985)

15.       Richards, R., Tattersfield, A.E.: Bronchial β-adrenoreceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects. Br. J. Pharmacol. 20: 459 (1985)

16.       Reeves, R.A., From, G.L.A., Paul, W., Leenen, F.H.H.: Nadolol, propranolol and thyroid hormones: Evidence for a membrane-stabilizing action of propranolol. Clin. Pharmacol. Ther. 37: 157 (1985)

17.       Heyma, P., Larkins, R.G., Higginbotham, L., Ng, K.W.: Propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine. Br. Med. J. 2: 24(1980)

18.       Myers, M.G., Hope-Gill, H.F.: Effect of d- and dl-propranolol on glucose-stimulated insulin release. Clin. Pharmacol Ther. 25: 303 (1979)

19.       Louis, W.J., McNeil, J.J., Drummer, O.H.: Pharmacology of combined α-β-blockade I. Drugs 28 (suppl. 2): 16 (1984)

20.       Ney, U.M.: Enhancement of airway sensitivity to histamine in guinea-pigs by β-adrenoreceptor blocking agents. Br. J. Pharmacol. 78 (suppl): 153P (1983)

21.       Fraunfelder, F.T., Barker, A.F.: Respiratory effects of timolol. N. Engl. J. Med. 311: 1441 (1984)

22.       Keates, E.U., Stone, R.: Effect of D-timolol on intraocular pressure in patients with ocular hypertension. Am. J. Opthalmol. 98: 73 (1984)

23.       Rowland, E., Perrins, E.J., Donaldson, R.M., Richards, A.F.: D-Sotalol – the clinical electrophysiological effects of a new class III antiarrythmic agent. Br. Heart J. 53: 87 (1985)

27.       El-Ackad, T.M., Panidis, I.P., Michelson, E.L. et al.: The relative cardiac beta-blocking potency of oral labetalol and its isomer SCH 19927 in normotensive subjects. Clin. Res. 32: 330A (1984)

25.       Prichard, B.N.C.: Combined a- and β-receptor inhibition in the treatment of hypertension. Drug 28 (suppl. 2): 51 (1984)

26.       Sybertz, E.J., Sabin, C.S., Pula, K.K., Vander Vliet, G., Glennon, J., Gold, E.J., Baum, T.: Alpha and beta adreno- receptor blocking properties of labetalol and its R.R-isomer, SCH 19927.7. Pharmacol. Exp. Ther. 275/435(1981)

28.       Dage, R.C., Cheng, H.C., Woodward, J.K.: Cardiovascular properties of medroxalol, a new hypertensive drug. J. Cardiov. Pharmacol. 3: 299 (1981)

29.       Schechter, P.J., Tanskanen, A., Tuomilehto, J„ Koch- Weser J.: Treatment of mild and moderate hypertension with medoxalol, an alpha- and beta-adrenergic antagonist. J. Cardiovasc. Pharmacol 4: 955 (1982)

30.       Cheng, H.C., Reavis, O.K., Grisar, G.M., Claxton, G.P., Weimer, D.L., Woodward, J.K.: Anti-hypertensive and adrenergic receptor blocking properties of enantiomers of medroxalol. Life Sci. 27: 2529 (.1980)

31.       White, N.J., Looareesuman, S., Warrell, D.A.: Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J. Cardiovasc. Pharmacol. 5: 173 (1983)

32.       Tickn, M.K., Rastogi, S.K., Thyagarajan, R.: Separate sites of action of optical isomers of 1-methyl-5-phenyl-5-pro-pylbarbituric acid with opposite pharmacological activities at the GABA receptor complex. Eur. J. Pharmacol. 112: 1 (1985)

33.       Ho, I.Κ., Harris, R.A.: Mechanisms of action of barbiturates. Ann. Rev. Pharmacol. Toxicox. 21: 83 (1981)

34.       Hutt, A.J., Caldwell, J.: The metabolic chiral inversion of 2- arylpropionic acids – a novel route with pharmacological consequences. J. Pharm. Pharmacol. 35: 693 (1983)

35.       Jamali, F.: Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur. J. Durg Metab. Pharmacokin. 13: 1 (1988)

36.       Williams, Κ., Day, R., Knihinicki, R., Duffield, A.: The ste-reoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem. Pharmacol. 35: 3403 (1986)

37.       Caldwell, J., Marsh, M.V.: Interrelationships between xenobiotic metabolism and lipid biosynthesis. Biochem. Pharmacol. 32: 1667 (1983)

38.       Lee, E.J.D., Williams, Κ., Day, R., Graham, G., Champion, D.: Stereoselective disposition of ibuprofen enantiomers in man. Br. J. CHn. Pharmacol. 19: 669 (1985)

39.       Tamura, S., Kuzuna, S., Kawai, Κ.: Inhibition of prostaglandin biosynthesis by clindanac and related compounds: structural and conformational requirements for Psynthetase inhibition. J. Pharm. Pharmacol. 33: 29 (1981)

40.       Ruffolo, R.R., Messick, Κ.: Inotropic selectivity of dobutamine enantiomers in the pithet rat. J. Pharmacol. Exp. Ther. 235: 344 (1985)

41.       Ruffolo, R.R., Messick, Κ.: Effects of dopamine, (±) dobu-tamine and the (+)- and (—)-enantiomers of dobutamine on cardiac function in pithed rats. J. Pharmacol. Exp. Ther. 235: 558 (1985)

42.       Ruffolo, R.R., Messick, Κ.: Systemic hemodynamic effects of dopamine, (±) dobutamine, and the (±) and (-)-enantiomers of dobutamine in anesthetized normotensive rats. Eur. J. Pharmacol. 109: 173 (1985)

43.       Vlasses, P.H., Rotmensch, H.H., Swanson, B.N. et al.: Indacrinone: natriuretic and uricosuric effects of various ratios of its enantiomers in healthy men. Pharmacotherapy. 4: 272 (1984)

44.       White, P.F., Schuttler, J., Shafer, A. et al.: Comparative pharmacology of the ketamine isomers. Br. J. Anaesth. 57: 197 (1985)

45.       Janssen, P.A.J.: The levamisol story. In: Progress in Drug Research (E. Jucker, ed.), Vol. 20, p. 347, Birkhauser Verlag, Basel, 1976

46.       Cotzias, G.C., Papavasiliou, P.S., Gellene, R.: Modification of parkinsonism: chronic treatment with L-dopa. N. Engl. J. Med. 280: 337 (1969)

47.       Forest, W.H., Beer, J., Bellville, J.W. et al.: Analgesic and other effects of the d and l-isomers of pentazocine. CUn. Pharmacol. Ther. 10: 468 (1969)

48.       Ariens, E.J.: Stereochemistry: A source of problems in medicinal chemistry. Med. Res. Rev. 6: 451 (1986)

49.       Series on Chirality: Trends Pharmacol. Sci. 7: 20, 60, 112, 155, 200, 227, 281 (1986)

50.       Reynolds, G.P., Riederer, P.: Tranylcypromine isomers in the treatment of parkinson’s disease. Int. Pharmacopsychiatry 16: 30 (1981)

51.       Plessas, S.T.: Clinical pharmacology of antiarrhythmic drugs. Epitheor. Klin. Farmakol. Farmakokin. El. Ekd. 3: 211 (1984)

52.       Weidmann, P., Gerber, A., Laederach, Κ.: Calcium antagonists in the treatment of hypertension: a critical overview. Adv. Nephrol. 14: 197 (1985)

53.       Eichelbaum, M.: Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem. Pharmacol. 37: 93 (1988)

54.       Reid, J.L., Meredith, P.A., Pasanisi, F.: Clinical pharmacol aspects of calcium antagonists and their therapeutic role in hypertension. J. Cardiovasc. Pharmacol. 7 fsuppl. 4): S18 (1985)

55.       Echizen, H., Brecht, T., Niedergesaess, S., Vogelgesang, B., Eichelbaum, M.: The effect of dextro, levo and racemic verapamil on atrioventricular conduction in man. Am. Heart J. 109: 210 (1985)

56.       Ferry, D.R., Glossmann, H., Kaumann, A.J.: Relationships between the stereoselective negative ionotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br. J. Pharmacol. 84: 811 (1985)

57.       Satoh, Κ., Yanagisawa, T., Taira, N.: Coronary vasodilator and cardiac effects of optical isomers of verapamil in the dog. J. Cardiovasc. Pharmacol. 2: 309 (1980)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr